reports
- Jonathan Moreland
TRS TRIMAS CORPORATION
TLYS TILLYS
TCBI TEXAS CAPITAL BANCSHARES INC.
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
MTH MERITAGE HOMES CORPORATION
INUV INUVO INC
FFIN FIRST FINANCIAL BANKSHARES INC
CAL CALERES INC.
CABO CABLE ONE INC.
PATK PATRICK INDUSTRIES INC.
ADC AGREE REALTY CORPORATION
TTI TETRA TECHNOLOGIES INC.
UEIC UNIVERSAL ELECTRONICS INC.
VRA VERA BRADLEY INC.
CIA CITIZENS INC. CL A
CC CHEMOURS CO.
IOVA IOVANCE BIOTHERAPEUTICS INC
QTRX QUANTERIX CORPORATION
RSSS RESEARCH SOLUTIONS
BHC BAUSCH HEALTH COMPANIES INC.
BBDC BARINGS BDC INC.
YMAB Y-MABS THERAPEUTICS
ETON ETON PHARMACEUTICALS
IMUX IMMUNIC INC
BLDR BUILDERS FIRSTSOURCE
FNWB INC.
AMPY FIRST NORTHWEST BANCORP
DCTH AMPLIFY ENERGY
ENX DELCATH SYSTEMS
TSHA EATON VANCE NEW YORK MUNICIPAL BOND FUND
SMMT TAYSHA GENE THERAPIES
HLMN SUMMIT THERAPEUTICS INC
COOK HILLMAN SOLUTIONS CORP.
AIRS TRAEGER
GECC INC.
TYRA AIRSCULPT TECHNOLOGIES INC
NNUP GREAT ELM CAPITAL CORP
BHRB TYRA BIOSCIENCES INC
DPG NOCOPI TECHS INC
RNXT BURKE & HERBERT BANK & TR/VA
GTE DUFF & PHELPS GLOBAL UTIL INCOME FD
SRBK RENOVORX INC
NKGN GRAN TIERRA ENERGY INC.
MNR SR BANCORP INC
NBBK NKGEN BIOTECH INC
NCDL MACH NATURAL RESOURCES LP
SDHY NB BANCORP INC.
ABL NUVEEN CHURCHILL DIRECT LENDING CORP
WHLR PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
ABACUS GLOBAL MANAGEMENT INC.
WHEELER REAL ESTATE INVESTMENT TRUST INC.
- Jonathan Moreland
PLUG PLUG POWER INC.
PBF PBF ENERGY INC. CLASS A
BRKR BRUKER CORPORATION
UEIC UNIVERSAL ELECTRONICS INC.
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
BRT BRT APARTMENTS
QTRX QUANTERIX CORPORATION
RFL RAFAEL HOLDINGS CL B
BBDC BARINGS BDC INC.
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
DLHC DALEIGH HOLDINGS CORP
RNXT RENOVORX INC
- Jonathan Moreland
WSR WHITESTONE REIT
TTSH TILE SHOP HOLDINGS INC.
TRS TRIMAS CORPORATION
TLYS TILLYS
TCBI TEXAS CAPITAL BANCSHARES INC.
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
MCY MERCURY GENERAL CORPORATION
FLO FLOWERS FOODS INC.
CTBI COMMUNITY TRUST BANCORP INC.
BUSE FIRST BUSEY CORPORATION
PATK PATRICK INDUSTRIES INC.
VFF VILLAGE FARMS INTERNATIONAL IN
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
CIA CITIZENS INC. CL A
BDL FLANIGAN'S ENTERPRISES INC.
CC CHEMOURS CO.
NHF NEXPOINT CREDIT STRATEGIES FUN
IOVA IOVANCE BIOTHERAPEUTICS INC
RSSS RESEARCH SOLUTIONS
RFL RAFAEL HOLDINGS CL B
BBDC BARINGS BDC INC.
YMAB Y-MABS THERAPEUTICS
REZI RESIDEO TECHNOLOGIES
IMUX INC.
FNWB IMMUNIC INC
XRX FIRST NORTHWEST BANCORP
AMPY XEROX HOLDINGS CORPORATION
VLA AMPLIFY ENERGY
TSHA ARBOR METALS
INNV TAYSHA GENE THERAPIES
SMMT INNOVAGE HOLDING
AFBI SUMMIT THERAPEUTICS INC
COOK AFFINITY BANCSHARES
TYRA INC.
BHRB TRAEGER
DPG INC.
VFC TYRA BIOSCIENCES INC
UHG BURKE & HERBERT BANK & TR/VA
GENK DUFF & PHELPS GLOBAL UTIL INCOME FD
SRBK VF CORPORATION
NKGN UNITED HOMES GROUP INC
NCDL GEN RESTAURANT GROUP INC
SDHY SR BANCORP INC
NEO NKGEN BIOTECH INC
JEQ NUVEEN CHURCHILL DIRECT LENDING CORP
LION PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
SLS NEO CORPORATE PUBLIC COMPANY LIMITED
ABL THE JAPAN EQUITY FUND
INC.
LIONSGATE STUDIOS CORP
SELLAS LIFE SCIENCES GROUP INC
ABACUS GLOBAL MANAGEMENT INC.
- Jonathan Moreland
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
PEB PEBBLEBROOK HOTEL TRUST
MG MISTRAS GROUP
ELY CALLAWAY GOLF COMPANY
NHF NEXPOINT CREDIT STRATEGIES FUN
IOVA IOVANCE BIOTHERAPEUTICS INC
MPB MID PENN BANCORP INC.
RSSS RESEARCH SOLUTIONS
BBDC BARINGS BDC INC.
AMPY AMPLIFY ENERGY
COOK TRAEGER
STGW INC.
TYRA STAGWELL INC
NCDL TYRA BIOSCIENCES INC
ABL NUVEEN CHURCHILL DIRECT LENDING CORP
ABACUS GLOBAL MANAGEMENT INC.
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these employees options to purchase an aggregate of 26,350 shares of the Company’s common stock with an exercise price of $9.98, the closing trading price of the Company’s common stock on the Nasdaq Global Market on t...
- Jonathan Moreland
SON SONOCO PRODUCTS COMPANY
NCR NCR CORPORATION
UNH UNITEDHEALTH GROUP INCORPORATED
RYAM RAYONIER ADVANCED MATERIALS INC
PLUG PLUG POWER INC.
PENN PENN NATIONAL GAMING INC.
PEB PEBBLEBROOK HOTEL TRUST
OEC ORION ENGINEERED CARBONS SA
MTX MINERALS TECHNOLOGIES INC.
MTDR MATADOR RESOURCES COMPANY
MO ALTRIA GROUP INC
LGND LIGAND PHARMACEUTICALS INCORPORATED
JRVR JAMES RIVER GROUP HOLDINGS LTD
HUN HUNTSMAN CORPORATION
HUM HUMANA INC.
ASB ASSOCIATED BANC-CORP
NEWT NEWTEK BUSINESS SERVICES INC.
RLMD RELMADA THERAPEUTICS
VFF VILLAGE FARMS INTERNATIONAL IN
HTLD HEARTLAND EXPRESS INC.
VSH VISHAY INTERTECHNOLOGY INC.
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
BXC BLUELINX HOLDINGS
GBLI GLOBAL INDEMNITY PLC
AMBC AMBAC FINANCIAL GROUP INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
CARS CARS.COM INC.
BRT BRT APARTMENTS
SNBR SLEEP NUMBER CORPORATION
MBIN MERCHANTS BANCORP
PMTS CPI CARD GROUP
LILA LIBERTY LATIN AMERICA A
COLD AMERICOLD REALTY TRUST
BBDC BARINGS BDC INC.
UTGN UTG
RPAY REPAY HOLDINGS (A)
XRX XEROX HOLDINGS CORPORATION
VLA ARBOR METALS
ONEW ONEWATER MARINE
MTCH MATCH GROUP INC.
PRG PROG HOLDINGS
MINM INC.
CIVI MINIM
UDMY INC.
OGN CIVITAS RESOURCES INC
OPAL UDEMY INC
PRME ORGANON & CO
VFC OPAL FUELS INC
PHIN PRIME MEDICINE INC
NCDL VF CORPORATION
FIP PHINIA INC
FG NUVEEN CHURCHILL DIRECT LENDING CORP
HCWB FTAI INFRASTRUCTURE INC
NEO F AND G ANNUITIES AND LIFE
INC.
HCW BIOLOGICS INC
NEO CORPORATE PUBLIC COMPANY LIMITED
Cartesian Therapeutics Announces First Participant Enrolled in the Pha...
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG). Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous engineered chimeric anti...
- Jonathan Moreland
LIND LINDBLAD EXPEDITIONS HOLDINGS
BXC BLUELINX HOLDINGS
GPMT GRANITE POINT MORTGAGE TRUST INC.
NHF NEXPOINT CREDIT STRATEGIES FUN
MPB MID PENN BANCORP INC.
NWPP NEW PEOPLES BANKSHARES INC.
BBDC BARINGS BDC INC.
MIDD THE MIDDLEBY CORPORATION
ENR EDGEWELL PERSONAL CARE COMPANY
AVTR AVANTOR
VLA INC.
HQL ARBOR METALS
ONEW TEKLA LIFE SCIENCES INVESTORS
ZIP ONEWATER MARINE
UDMY ZIPRECRUITER
OPAL INC.
PRME UDEMY INC
SDHC OPAL FUELS INC
FIP PRIME MEDICINE INC
EVM SMITH DOUGLAS HOMES CORP
GF FTAI INFRASTRUCTURE INC
FINS EATON VANCE INSD CALIF MUN BD FD
THE NEW GERMANY FUND
INC.
ANGEL OAK FINANCIAL STRATEGIES INCOME TERM TRUST
- Jonathan Moreland
MMLP MARTIN MIDSTREAM PARTNERS L.P.
JRVR JAMES RIVER GROUP HOLDINGS LTD
NEWT NEWTEK BUSINESS SERVICES INC.
RLMD RELMADA THERAPEUTICS
BBDC BARINGS BDC INC.
ENR EDGEWELL PERSONAL CARE COMPANY
INZY INOZYME PHARMA
ALIT ALIGHT
WEST INC. / DELAWARE
STRW WESTROCK COFFEE COMPANY LLC
SRBK STRAWBERRY FIELDS REIT INC.
SDHC SR BANCORP INC
EVM SMITH DOUGLAS HOMES CORP
TXO EATON VANCE INSD CALIF MUN BD FD
GF MORNINGSTAR PARTNERS
GREE L.P.
HCWB THE NEW GERMANY FUND
INC.
GREENIDGE GENERATION HLDGS INC
HCW BIOLOGICS INC
Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annua...
Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ FREDERICK, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025, at 9:00 a.m. ET. A live webcast of the presentation and fireside chat is expected to be accessible in th...
Cartesian Therapeutics Reports First Quarter 2025 Financial Results an...
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in 2H25 Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected in 2H25 Approximately $182.1 million cash, cash equivalents and restricted cash as of Marc...
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., May 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On May 1, 2025, the Company issued to these employees options to purchase an aggregate of 27,700 shares of the Company’s common stock with an exercise price of $12.27, the closing trading price of the Company’s common stock on the Nasdaq Glo...
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sust...
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 Deepest and most compelling sustained responses observed in Descartes-08-treated participants who did not have prior exposure to biologic therapies, with an average 7.1-point reduction in MG-ADL and 57% of patients in this subgrou...
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On April 1, 2025, the Company issued to these employees options to purchase an aggregate of 31,000 shares of the Company’s common stock with an exercise price of $12.49, the closing trading price of the Company’s common stock on the Nasd...
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtu...
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 2:15 p.m. ET. A live webcast of the presentation and fireside chats is expected to be accessible in the Events section of the C...
Cartesian Therapeutics Reports Full Year 2024 Financial Results and Pr...
Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial Phase 2 trial of Descartes-08 in systemic lupus erythematosus ongoing with expected data readout in 2H25 Company expects to initiate Phase 2 pediatric basket trial of Decartes-08 in select autoimmune indications in 2H25 Dosing underway in first-in-human Phase 1 trial of Descartes-15 Approximately $214.3...
Cartesian Therapeutics Announces New Employment Inducement Grant
Cartesian Therapeutics Announces New Employment Inducement Grant FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to one new employee. On March 3, 2025, the Company issued to this employee an option to purchase 2,650 shares of the Company’s common stock with an exercise price of $17.50, the closing trading price of the Company’s common stock on the Nasdaq Global Mar...
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Cartesian Therapeutics to Participate in Upcoming Investor Conferences FREDERICK, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in February and March: A fireside chat at the H.C. Wainright & Co. 3rd Annual Cell Therapy Virtual Conference at 1:00 p.m. ET on Tuesday, February 25, 2025A presentation at the TD Cowen 45th Annual Health Care Conference...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Discover Financial Services and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 7 February 2025 in which we reassessed the appropriateness of the ratings in th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.